# Study of Clinical Non-inferiority of Actparin® (Laboratorio Bergamo) Compared to Heparin Sodium (APP Pharmaceuticals), in Patients With Chronic Renal Failure

Study · id `cardio:ct-nct01346215` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01346215](<https://clinicaltrials.gov/study/NCT01346215>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01346215

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 132 participants.

## Technical summary

Registry record NCT01346215. Randomized; single masking; primary purpose prevention. Start 2011-10 (registry gives no type); primary completion 2011-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 132 participants (planned count; ClinicalTrials.gov record NCT01346215, source copy `cardio:ctgov-nct01346215-2011-05-02`, retrieved 2026-10-26)
- Start date: 2011-10 (registry gives no type) (ClinicalTrials.gov record NCT01346215, source copy `cardio:ctgov-nct01346215-2011-05-02`, retrieved 2026-10-26)
- Primary completion: 2011-12 (anticipated) (ClinicalTrials.gov record NCT01346215, source copy `cardio:ctgov-nct01346215-2011-05-02`, retrieved 2026-10-26)
- Completion: 2012-02 (anticipated) (ClinicalTrials.gov record NCT01346215, source copy `cardio:ctgov-nct01346215-2011-05-02`, retrieved 2026-10-26)
- Countries: Brazil (ClinicalTrials.gov record NCT01346215, source copy `cardio:ctgov-nct01346215-2011-05-02`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01346215-2011-05-02`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study of Clinical Non-inferiority of Actparin® (Laboratorio Bergamo) Compared to Heparin Sodium (APP Pharmaceuticals), in Patients With Chronic Renal Failure
- Condition: Chronic Renal Failure
- Intervention (Biological): heparin sodium
- Intervention (Biological): heparin sodium
- Lead sponsor: Laboratório Químico Farmacêutico Bergamo Ltda.
- Lead sponsor class: INDUSTRY
- Collaborator: Azidus Brasil
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry intervention name matches this record: Heparin (`cardio:heparin`)
- Registry intervention is a member of this class by a sourced record link: Heparins and low-molecular-weight heparins (`cardio:heparins-and-low-molecular-weight-heparins`)
- Registry intervention is a member of this class by a sourced record link: Anticoagulants (`cardio:anticoagulants`)

## Provenance

Content hash: f74dbe581e33382c63bcbc872089b71f87db4ca642cbfb303fbed7b2b7b10aa3
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
